Skip to content

Improving Partnerships With Family Members of ICU Patients

Improving Partnerships With Family Members of ICU Patients: The IMPACT Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02920086
Acronym
IMPACT
Enrollment
150
Registered
2016-09-30
Start date
2017-05-09
Completion date
2020-12-31
Last updated
2019-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critical Illness

Brief summary

The purpose of this study is to improve the outcomes of critically ill older patients and the health outcomes of their families by capacitating and partnering with families in optimizing patient/family centered care.

Detailed description

There is a pressing need to improve the care of critically ill older patients. For critically ill patients who are frequently unable to participate in their own care and decision-making, partnering with their family members is particularly important for improving experiences and outcomes of care for both patients and families. However, the optimal means by which families engage in the role they play, and how best to capacitate them as advocates and partners in care while helping them maintain their own wellbeing, is not known. The IMPACT trial will evaluate two interventions, each with a separate context, but similar in that they empower and support families; one focused on involvement in care, and the other focused on involvement in decision-making. The first is a nutrition intervention The OPTimal nutrition by Informing and Capacitating family members of best practices (OPTICs) intervention, a multi-faceted strategy to engage and empower family members to advocate for and audit best nutrition practices in their family members. The second is a decision support intervention. The REALISTIC-80 Decision Support Intervention, is a web-based tool (www.myicuguide.com) to support families in shared decision-making about goals of medical treatments. The investigators propose to conduct a mixed methods multi-centre, open-label, randomized, clinical trial involving 3 groups (2 active interventions and a usual care group). The overall goal of this study is to demonstrate that the multi-faceted nutritional strategies that engage families in care of their family member tested in this trial will increase nutritional intake and optimize physical recovery in older critically ill patients at high nutrition risk.

Interventions

* The OPTimal nutrition by Informing and Capacitating family members of best practices (OPTICS) intervention * Nutritional education will be provided to ICU patents' families by a dietitian * Tracking of nutritional information by family * Encouragement for families to advocate for two or more Oral Nutritional Supplements per day for the patients (approximately 400 kcal/day)

OTHERDecision Support Program

* Families will be provided with a web-based decision support tool (My ICU Guide) * Families will meet with the ICU medical team early in ICU stay to review goals of care

Sponsors

Canadian Institutes of Health Research (CIHR)
CollaboratorOTHER_GOV
Griffith University
CollaboratorOTHER
Clinical Evaluation Research Unit at Kingston General Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
55 Years to No maximum
Healthy volunteers
No

Inclusion criteria

for Patients: 1a) \> 60 years of age OR 1b) 55 years to 59 years old with one or more of the following diagnoses: * Chronic obstructive lung disease - 2 of the 4 of: baseline PaCO2 of \> 45 torr, cor pulmonale; respiratory failure episode within the preceding year; forced expiratory volume in 1 sec \<0.5 L. * Congestive heart failure - New York Heart Association class IV symptoms and left ventricular ejection fraction \< 25%. * Cirrhosis - confirmed by imaging studies or documentation of esophageal varices and one of three conditions: a) hepatic coma, b) Child's class C liver disease, or c) Child's class B liver disease with gastrointestinal bleeding. * Cancer - metastatic cancer or stage IV lymphoma. * End-stage dementia (inability to perform all ADLs, mutism or minimal verbal output secondary to dementia, bed-bound state prior to acute illness) 2) Have a projected duration of ICU dependency of \>72 hours from time of final assessment. We define ICU dependency as the need for one or more of the following: * Mechanical ventilation * Non-invasive ventilation * Renal replacement therapy * Vasopressors or * Artificial nutrition because of their underlying illness

Exclusion criteria

for Patients: * Patients who are not expected to remain alive in ICU for 72 hours after initial screening (physician judgment) or for whom life-sustaining treatments are expected to be withdrawn in the subsequent 72 hours (as sufficient time will be required for implementation of the study interventions) * Uncomplicated elective surgical patients (regardless of age) * Patients who have received organ transplantation during this hospitalization Inclusion Criteria for Family Member: * 18 years of age or older, * present and expected to visit regularly (minimum about 3 times a week) while the patient is in hospital * the nominated or legally appointed substitute decision-maker * able to communicate in English (verbally and in writing).

Design outcomes

Primary

MeasureTime frameDescription
Nutritional adequacy during the ICU stayUp to 30 days in ICU
Consumption of Oral Nutritional SupplementsFirst four weeks once on ward
Intake on hospital wards (3 day calorie count)First four weeks once on ward
Hand grip strengthAt or before hospital discharge or up to 90 daysHydraulic hand dynamometer
Use of shared-decision making (OPTION tool)Within first week in ICU
Change in decisional conflict1 week10-item Decisional Conflict Scale
Family satisfaction with decision-making1 week
Overall family satisfaction with ICUAt ICU discharge, an average of 12 days

Countries

Australia, Canada, United States

Contacts

Primary ContactDaren Heyland, MD
dkh2@queensu.ca613-549-6666

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026